Company intelligence / Profile preview

TellBio Inc.

Beverly, Massachusetts, United Statestellbio.com ↗

Ownership: Private
Employees: ~1
Development stage: Preclinical

Overview

TellBio's technology has demonstrated that analysis of circulating tumor cells can predict survival among patients with metastatic castration-resistant prostate cancer receiving Radium-223. Their technology has also shown promise in predicting response to therapy in patients with progressive metastatic breast cancer.[1][6]

Therapeutic areas: Oncology
Modalities: DiagnosticsTherapeutics
Industry: Biotech

Partnerships

Massachusetts General Hospital

Beyond the preview

Go deeper on TellBio Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TellBio Inc..

Explore the full profile